Search

Your search keyword '"Mark A. Wainberg"' showing total 699 results

Search Constraints

Start Over You searched for: Author "Mark A. Wainberg" Remove constraint Author: "Mark A. Wainberg"
699 results on '"Mark A. Wainberg"'

Search Results

101. ChemInform Abstract: Flueggethers B-D, Securinega Alkaloids with Rare Oligomerizing Pattern from Flueggea virosa

102. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance

104. Selection of the R263K and H51Y resistance substitutions for DTG causes diminished integration and explains the lack of clinically significant drug resistance to this compound

105. CRISPR/Cas9: a double-edged sword when used to combat HIV infection

106. ChemInform Abstract: Flueggether A and Virosinine A, anti-HIV Alkaloids from Flueggea virosa

107. Might dolutegravir be part of a functional cure for HIV?

108. ChemInform Abstract: New Securinega Alkaloids with anti-HIV Activity from Flueggea virosa

109. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors

110. Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity

111. Molecular Mechanism of Antagonism between the Y181C and E138K Mutations in HIV-1 Reverse Transcriptase

112. In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor

113. Maraviroc and Other HIV-1 Entry Inhibitors Exhibit a Class-Specific Redistribution Effect That Results in Increased Extracellular Viral Load

114. HIV gp120 H375 Is Unique to HIV-1 Subtype CRF01_AE and Confers Strong Resistance to the Entry Inhibitor BMS-599793, a Candidate Microbicide Drug

115. The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs

116. In Vitro Resistance Profile of the Candidate HIV-1 Microbicide Drug Dapivirine

117. Insights into HIV-1 pathogenesis through drug discovery: 30 years of basic research and concerns for the future

118. Transmission Clustering Drives the Onward Spread of the HIV Epidemic Among Men Who Have Sex With Men in Quebec

119. Development of Antiretroviral Drug Resistance

120. Transcription of Preintegrated HIV-1 cDNA Modulates Cell Surface Expression of Major Histocompatibility Complex Class I via Nef

121. Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes

122. Complete inactivation of HIV-1 using photo-labeled non-nucleoside reverse transcriptase inhibitors

123. Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes

124. HIV-1 Protease Codon 36 Polymorphisms and Differential Development of Resistance to Nelfinavir, Lopinavir, and Atazanavir in Different HIV-1 Subtypes

125. The M230L Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutation in HIV-1 Reverse Transcriptase Impairs Enzymatic Function and Viral Replicative Capacity

126. Reconsidering the lifetime deferral of blood donation by men who have sex with men

127. Multi-Low-Dose Mucosal Simian Immunodeficiency Virus SIVmac239 Challenge of Cynomolgus Macaques Immunized with 'Hyperattenuated' SIV Constructs

128. Canadian Consensus Guidelines for the Optimal Use of Maraviroc in the Treatment of HIV-Infected Adults

129. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine

130. HIV inactivation by cross-linking of photo-labeled anti-retroviral compounds with HIV reverse transcriptase

131. Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel

132. Antiretroviral Drug Resistance in Human Immunodeficiency Virus Type 2

133. Template Usage Is Responsible for the Preferential Acquisition of the K65R Reverse Transcriptase Mutation in Subtype C Variants of Human Immunodeficiency Virus Type 1

134. Antiviral drug development: progress and pitfalls

135. Discrepancies in Assignment of Subtype/Recombinant Forms by Genotyping Programs for HIV Type 1 Drug Resistance Testing May Falsely Predict Superinfection

136. Antiretroviral Therapy

137. Gender and the Use of Antiretroviral Treatment in Resource-Constrained Settings: Findings from a Multicenter Collaboration

138. Variations in Reverse Transcriptase and RNase H Domain Mutations in Human Immunodeficiency Virus Type 1 Clinical Isolates Are Associated with Divergent Phenotypic Resistance to Zidovudine

139. In Vitro Antiviral Activity and Cross-Resistance Profile of PL-100, a Novel Protease Inhibitor of Human Immunodeficiency Virus Type 1

140. Review: Immunologic Response to Protease Inhibitor-Based Highly Active Antiretroviral Therapy: A Review

141. Strategies for the optimal sequencing of antiretroviral drugs toward overcoming and preventing drug resistance

142. Arginine Methylation of the Human Immunodeficiency Virus Type 1 Tat Protein by PRMT6 Negatively Affects Tat Interactions with both Cyclin T1 and the Tat Transactivation Region

143. Kinetics of Inhibition of HIV Type 1 Reverse Transcriptase-Bearing NRTI-associated Mutations by Apricitabine Triphosphate

144. Apricitabine: A Novel Deoxycytidine Analogue Nucleoside Reverse Transcriptase Inhibitor for the Treatment of Nucleoside-Resistant HIV Infection

145. High Rates of Forward Transmission Events after Acute/Early HIV‐1 Infection

146. Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations

147. Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase

148. World AIDS Day 2015

149. Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy

150. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance

Catalog

Books, media, physical & digital resources